Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Urologic Neoplasms 1Neoplasms 1Melanoma 1Colonic Neoplasms 1

Interventions

pembrolizumab 6cemiplimab 3Cyclophosphamide 3temsirolimus 2palbociclib 2cediranib 2Therapeutics 2Radiotherapy 2Radiosurgery 2Psychiatric Rehabilitation 2Paclitaxel 2Oxaliplatin 2Nivolumab 2Methods 2Magnetic Resonance Spectroscopy 2Leucovorin 2Gemcitabine 2Fluorouracil 2Drug Therapy 2Docetaxel 2Cisplatin 2Capecitabine 2Biological Therapy 22,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 2ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1tanespimycin 1sonidegib 1sargramostim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colonic Neoplasms × Immunoglobulins, Intravenous × Dermatologic × Clear all
NCT00294476 2006-10-12

IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma

GammaCan

Phase 2 Unknown
30 enrolled
DermatologicGastrointestinalGenitourinary

Colonic Neoplasms, Melanoma, Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡